Assignee
KALVISTA PHARMACEUTICALS LTD
GB·23 granted patents·21 pending applications·108 citations·filing 2013–2024
Top patents by PatentIndex Score
44 records- 0191US10364238B2N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2015·Granted Jul 30, 2019·8 cites·16 claims
- 0289US10781181B2N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2015·Granted Sep 22, 2020·6 cites·36 claims
- 0389US10611758B2N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2019·Granted Apr 7, 2020·4 cites·1 claims
- 0489US10221161B2Inhibitors of plasma kallikreinKALVISTA PHARMACEUTICALS LTD·Filed 2014·Granted Mar 5, 2019·13 cites·32 claims
- 0588US9533987B2Heterocyclic derivatesKALVISTA PHARMACEUTICALS LTD·Filed 2014·Granted Jan 3, 2017·19 cites·27 claims
- 0688US9512065B2Polymorphs of N-[(R)-1-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-benzamide hydrochlorideKALVISTA PHARMACEUTICALS LTD·Filed 2013·Granted Dec 6, 2016·19 cites·17 claims
- 0787US2025074903A1N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein InhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2024·Application pending·0 cites
- 0885US9670157B2Benzylamine derivativesKALVISTA PHARMACEUTICALS LTD·Filed 2014·Granted Jun 6, 2017·13 cites·30 claims
- 0984US10752607B2Polymorphs of N-[(6-cyano-2-fluoro)-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide as kallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2017·Granted Aug 25, 2020·5 cites·37 claims
- 1084US9738641B2Bicyclic inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2014·Granted Aug 22, 2017·13 cites·29 claims
- 1183US11230537B2Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[2-oxopyridin-1-yl)methyl]phenyl} methyl)pyrazole-4-carboxamide as iallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2017·Granted Jan 25, 2022·3 cites·11 claims
- 1279US9834513B2Benzylamine derivativesKALVISTA PHARMACEUTICALS LTD·Filed 2017·Granted Dec 5, 2017·4 cites·26 claims
- 1377US2022289729A1N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Kallikrein InhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 1476US11234939B2Dosage forms comprising a plasma kallikrein inhibitorKALVISTA PHARMACEUTICALS LTD·Filed 2018·Granted Feb 1, 2022·1 cites·53 claims
- 1576US11001578B2N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2019·Granted May 11, 2021·0 cites·30 claims
- 1675US11084809B2N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2020·Granted Aug 10, 2021·0 cites·15 claims
- 1772US11739068B2Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereofKALVISTA PHARMACEUTICALS LTD·Filed 2021·Granted Aug 29, 2023·0 cites·13 claims
- 1872US11198691B2N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2020·Granted Dec 14, 2021·0 cites·24 claims
- 1970US2024199573A1Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereofKALVISTA PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 2069US2023250080A1Enzyme inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 2167US2022153724A1Inhibitors Of Plasma KallikreinKALVISTA PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 2266US2025281397A1Formulations of a plasma kallikrein inhibitorKALVISTA PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 2364US11613527B2Enzyme inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2021·Granted Mar 28, 2023·0 cites·46 claims
- 2463US2022002275A1Enzyme inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 2561US11242333B2Inhibitors of plasma kallikreinKALVISTA PHARMACEUTICALS LTD·Filed 2019·Granted Feb 8, 2022·0 cites·15 claims
- 2656US11180484B2Pyrazole derivatives as plasma kallikrein inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2017·Granted Nov 23, 2021·0 cites·4 claims
- 2755US2024122909A1Treatments of hereditary angioedemaKALVISTA PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 2854US11584735B2Solid forms of a plasma kallikrein inhibitor and salts thereofKALVISTA PHARMACEUTICALS LTD·Filed 2018·Granted Feb 21, 2023·0 cites·15 claims
- 2954US2024059691A1Enzyme inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 3054US2023381162A1Treatments of angioedemaKALVISTA PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 3153US2024327412A1Factor xiia inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 3250US9849100B2Pharmaceutical compositions suitable for parenteral administration comprising aqueous suspensions of benzylamine derivatives having low solubilitiesKALVISTA PHARMACEUTICALS LTD·Filed 2014·Granted Dec 26, 2017·0 cites·35 claims
- 3350US2020325116A1Solid forms of a plasma kallikrein inhibitor and salts thereofKALVISTA PHARMACEUTICALS LTD·Filed 2018·Application pending·0 cites
- 3448US2022226293A1Treatments of angioedemaKALVISTA PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 3548US2022401390A1Treatments of diabetic macular edema and impaired visual acuityKALVISTA PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 3648US2022289727A1Enzyme inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 3747US10478409B2Pharmaceutical compositionsKALVISTA PHARMACEUTICALS LTD·Filed 2017·Granted Nov 19, 2019·0 cites·32 claims
- 3846US2020261383A1Pharmaceutical compositionsKALVISTA PHARMACEUTICALS LTD·Filed 2018·Application pending·0 cites
- 3946US2022363668A1Enzyme inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 4046US2022218680A1Treatments of hereditary angioedemaKALVISTA PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 4143US2022298138A1Enzyme inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2019·Application pending·0 cites
- 4243US2022298141A1Enzyme inhibitorsKALVISTA PHARMACEUTICALS LTD·Filed 2019·Application pending·0 cites
- 4341US9234000B2Benzylamine derivatives as inhibitors of plasma kallikreinKALVISTA PHARMACEUTICALS LTD·Filed 2015·Granted Jan 12, 2016·0 cites·13 claims
- 4436US2020317639A1Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1yl)methyl]phenyl}methyl)pyrazole-4-carboxamideKALVISTA PHARMACEUTICALS LTD·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when KALVISTA PHARMACEUTICALS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →